Eltrombopag in treatment of refractory primary immune thrombocytopenia: case report

We present clinical case that demonstrates high efficiency of eltrombopag for the treatment of immune thrombocytopenia. It is shown that stable effect may persist after a course of eltrombopag therapy during 2 months. Eltrombopag is highly effective with repeated use.

• G.A. Dudina Moscow Regional Scientific-Research Clinical Institute n.a. M.F. Vladimirskiy, Moscow, Russian Federation ; Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского, Москва, Российская Федерация
• I.N. Kontievskiy Moscow Regional Scientific-Research Clinical Institute n.a. M.F. Vladimirskiy, Moscow, Russian Federation ; Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского, Москва, Российская Федерация
• V.N. Perova Municipal Clinical City Hospital, Dubna, Russian Federation ; МУЗ Дубнинская ГБ, Дубна, Российская Федерация

1. Kalota A., Brennan K., Erickson-Miller C.L. et al. Effects of SB559457, a novel small molecule thrombopoietin receptor (TpoR) agonist, on human hematopoietic cell growth and diff erentiation. Blood 2004; 104: 796a (abstr 2913). DOI: https://doi.org/10.1182/blood.V104.11.2913.2913
2. Bussel B., Provan D., Shamsi T. et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet 2009; 373: 641–8. DOI: https://doi.org/10.1016/S0140-6736(09)60402-5
3. Cheng G., Saleh M.N., Marcher C. et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet 2010; 376: 1–10. DOI: https://doi.org/10.1016/S0140-6736(10)60959-2
4. Bussel J.B., Saleh M.N., Vasey S.Y. et al. Repeated short-term use of eltrombopag in patients with chronic immune thrombocytopenia (ITP). British Journal of Haematology (http:onlinelibrary.wiley.com/doi/10.1111/bjh.12169/full).